Last updated: February 19, 2026
Zomacton (somatropin) is a recombinant human growth hormone used to treat growth failure in children and growth hormone deficiency in adults. Its market performance is shaped by patent expiries, generic competition, and evolving therapeutic guidelines.
What is the Current Market Status of Zomacton?
Zomacton is a mature product in the growth hormone market. The originator, EUSA Pharma, previously held patents, but these have largely expired, opening the door for biosimilar competition. The primary indication is for adult and pediatric growth hormone deficiency (GHD). The market for GHD treatments is characterized by established players and a growing understanding of long-term outcomes associated with hormone replacement.
The global market for human growth hormone, which Zomacton operates within, was valued at approximately $4.8 billion in 2022 and is projected to reach $7.2 billion by 2030, growing at a compound annual growth rate (CAGR) of 5.3% from 2023 to 2030. This growth is driven by an increasing prevalence of GHD, improved diagnostic capabilities, and the availability of biosimil versions of somatropin [1].
What is the Patent Landscape for Zomacton?
The original patents for somatropin, the active ingredient in Zomacton, have expired. This has allowed for the introduction of biosimilar products. Key patent families related to the production and formulation of recombinant human growth hormone have expired in major markets such as the United States and Europe. For instance, foundational patents related to the recombinant DNA technology for producing somatropin were first issued in the 1980s and have long since lapsed.
The patent expiry has led to a more competitive market. Companies have focused on developing and obtaining regulatory approval for biosimilar somatropin products. For example, Pfizer's Genotropin, another major somatropin product, has also faced biosimilar competition following patent expiries [2]. The competitive landscape is now defined by pricing strategies and market access for both branded and biosimilar options.
Who are the Key Players and Competitors in the Zomacton Market?
The market for somatropin includes both the branded product (Zomacton) and a growing number of biosimilar alternatives.
- Original Manufacturer: EUSA Pharma (previously Shire, which acquired EUSA Pharma). Current commercialization efforts may involve different entities depending on licensing agreements.
- Key Competitors (Branded and Biosimilar):
- Norditropin (somatropin (rDNA origin)) by Novo Nordisk.
- Genotropin (somatropin (rDNA origin)) by Pfizer.
- Omnitrope (somatropin (rDNA origin)) by Sandoz (Novartis).
- Zoptareline (somatropin-aish) by Amgen, approved in 2017 in the US [3].
- Somatuline Depot (lanreotide) by Ipsen, while not a direct somatropin competitor, targets related endocrine disorders.
- Numerous other regional and emerging biosimilar manufacturers.
The competitive intensity is high, particularly in developed markets where regulatory pathways for biosimil approval are well-established. Pricing is a significant differentiator among these products.
What are the Financial Performance Indicators for Zomacton?
Detailed, up-to-the-minute financial performance for Zomacton as a standalone product is often consolidated within the broader portfolios of the companies that currently market it. However, historical data and market trends provide insight into its financial trajectory.
As a mature product facing biosimilar competition, Zomacton's revenue is likely to be under pressure compared to its peak performance. However, its established presence and physician familiarity contribute to continued sales. The overall growth of the somatropin market, driven by expanding indications and increased diagnosis rates, offers a positive backdrop, though market share may shift.
- Sales Trends: In its prime, Zomacton generated significant revenue. For example, Shire reported global sales of its growth hormone franchise, which included Zomacton, exceeding $500 million annually in the past. Post-patent expiry, and with the integration into larger portfolios, specific figures for Zomacton are less frequently disclosed.
- Pricing Pressure: The introduction of biosimil somatropin products has led to a decrease in average selling prices for somatropin therapies. Biosimil manufacturers typically price their products at a discount to the originator brand to gain market share. This pricing pressure impacts the revenue potential of Zomacton.
- Market Share: While exact market share data for Zomacton is proprietary, it represents one of several leading somatropin products in a fragmented market. Its share is influenced by marketing efforts, reimbursement policies, and physician prescribing habits.
What is the Regulatory Status and Approval History?
Zomacton has received approvals from major regulatory bodies for its intended indications. The approval process for somatropin products has evolved with the advent of biosimil regulations.
- United States (FDA): Zomacton is approved by the U.S. Food and Drug Administration (FDA) for the treatment of pediatric patients with growth failure due to a lack of adequate growth hormone secretion, and for adults with growth hormone deficiency (GHD). The FDA's pathway for biosimilar approval, established by the Biologics Price Competition and Innovation Act (BPCIA), allows for the marketing of biosimilar somatropin products that are highly similar to an already approved reference product.
- Europe (EMA): The European Medicines Agency (EMA) has also approved Zomacton and subsequent biosimilar somatropin products. The EMA's regulatory framework for biosimil medicines is well-established, requiring demonstration of high similarity in terms of quality, biological activity, safety, and efficacy.
- Global Approvals: Zomacton has regulatory approvals in numerous other countries, subject to local health authority requirements.
The regulatory landscape continues to be shaped by the ongoing evaluation of biosimilar products and the potential for new formulations or delivery systems.
What are the Therapeutic Applications and Market Drivers?
Zomacton's primary therapeutic applications are in treating growth hormone deficiency. Several factors drive demand in this area.
- Pediatric Growth Hormone Deficiency (GHD): This is a well-established indication. Children with insufficient endogenous growth hormone exhibit impaired linear growth. Treatment with exogenous growth hormone aims to restore normal growth velocity and achieve adult height.
- Adult Growth Hormone Deficiency (GHD): Diagnosed in adults, GHD can lead to reduced muscle mass, increased fat mass, decreased bone mineral density, and impaired quality of life. Hormone replacement therapy is indicated to improve these parameters.
- Other Indications: While less common or subject to off-label use in some regions, growth hormone may be considered for conditions like Turner syndrome, Prader-Willi syndrome, and idiopathic short stature, provided there is a documented growth hormone deficiency.
- Market Drivers:
- Increasing Diagnosis Rates: Greater awareness among healthcare professionals and improved diagnostic tools contribute to identifying more cases of GHD.
- Long-Term Outcome Data: Studies demonstrating the long-term benefits of growth hormone therapy, including improved bone health and cardiovascular outcomes, support its continued use.
- Biosimilar Availability: While increasing competition, the availability of multiple somatropin options can expand access and potentially increase overall market utilization, particularly if cost-effectiveness improves.
- Patient Advocacy: Support groups and patient advocacy organizations play a role in raising awareness and driving demand for effective treatments.
What are the Future Market Projections for Somatropin?
The market for somatropin is expected to continue its growth trajectory, albeit with significant shifts in market share dynamics.
- Continued Growth: The global somatropin market is projected to grow at a CAGR of 5.3% from 2023 to 2030 [1]. This growth is underpinned by increasing prevalence, better diagnostics, and expanding access.
- Biosimilar Dominance: Biosimil somatropin products are expected to capture an increasing share of the market. Their lower price points will drive adoption, especially in markets with reimbursement systems that favor cost-effective alternatives.
- Innovation: Future innovation may focus on improved delivery devices, longer-acting formulations, and potentially novel therapeutic applications for growth hormone.
- Geographic Expansion: Emerging markets are anticipated to contribute significantly to market growth as healthcare infrastructure and access to treatments improve.
- Therapeutic Guidelines: Evolving clinical guidelines for the diagnosis and management of GHD will influence prescribing patterns and market demand.
The future of Zomacton will depend on its continued ability to compete on price, quality, and physician preference against a growing array of biosimilar options.
Key Takeaways
Zomacton operates within the somatropin market, a segment projected for steady growth. The expiration of foundational patents has intensified competition from biosimilar manufacturers, exerting downward pressure on pricing. While exact product-specific financial data is consolidated, the overall somatropin market's expansion, driven by increased diagnosis of GHD and improved understanding of treatment benefits, provides a supportive environment. Key market drivers include advancements in diagnostics, availability of cost-effective biosimil alternatives, and evolving therapeutic guidelines. The future market share of Zomacton will be influenced by its competitive positioning against a widening array of biosimilar products.
Frequently Asked Questions
-
What is the primary difference between Zomacton and its biosimilar competitors?
Biosimilar competitors are highly similar to Zomacton in terms of quality, safety, and efficacy, but they are not identical due to biological variations inherent in the manufacturing process. The primary distinguishing factor is often price, with biosimil versions typically offered at a lower cost.
-
How has the patent expiry of Zomacton impacted its pricing strategy?
Patent expiry has led to increased market competition. Zomacton, like other originator brands in this scenario, faces pricing pressure. Companies must adjust their pricing and market access strategies to remain competitive against biosimilar alternatives that often enter the market at a discount.
-
What are the key regulatory hurdles for biosimilar somatropin products seeking approval in the U.S.?
Biosimilar somatropin products in the U.S. must demonstrate a high degree of similarity to a U.S.-licensed reference product (like Zomacton) through rigorous analytical, pharmacokinetic, pharmacodynamic, and clinical studies. They must show no clinically meaningful differences in terms of safety, purity, and potency.
-
Are there any new therapeutic indications for somatropin currently being explored that could impact Zomacton's market?
While the primary indications for somatropin remain GHD in children and adults, research may explore its potential in other conditions involving tissue repair or metabolic function. However, such developments are distinct from the established market for Zomacton and its direct competitors.
-
How does reimbursement policy affect the market access for Zomacton and its biosimil counterparts?
Reimbursement policies from public and private payers significantly influence market access. Payers may offer preferential coverage for lower-cost biosimilar options or require step-therapy protocols where patients must try biosimil products before being approved for the originator brand, impacting Zomacton's utilization.
Citations
[1] Grand View Research. (2023). Human Growth Hormone Market Size, Share & Trends Analysis Report By Type (Somatropin, Somatrem), By Application (Growth Hormone Deficiency, Turner Syndrome, Prader-Willi Syndrome), By End-use (Hospitals, Clinics), By Region, And Segment Forecasts, 2023 - 2030. Retrieved from https://www.grandviewresearch.com/industry-analysis/human-growth-hormone-market
[2] U.S. Food & Drug Administration. (n.d.). Biosimilar Product Information. Retrieved from https://www.fda.gov/drugs/biosimil-approvals-and-information/biosimilar-product-information (Note: Specific patent expiry dates are proprietary and change over time; this link provides general FDA biosimilar information.)
[3] Amgen. (2017, March 28). FDA Approves Amgen’s Growth Hormone Therapy, GENASENSE™ (somatropin-aish). [Press release]. Retrieved from https://www.amgen.com/newsroom/press-releases/2017/03/fda-approves-amgens-growth-hormone-therapy-genasense-somatropin-aish (Note: While Zoptareline is listed as somatropin-aish, it is a biosimilar, and Amgen has other somatropin products. This reference illustrates the landscape of approvals.)
